Target Mechanism-Based Whole-Cell Screening Identifies Bortezomib as an Inhibitor of Caseinolytic Protease in Mycobacteria
View/ Open
Author
Moreira, Wilfried
Ngan, Grace J. Y.
Low, Jian Liang
Poulsen, Anders
Chia, Brian C. S.
Ang, Melgious J. Y.
Yap, Amelia
Fulwood, Justina
Lakshmanan, Umayal
Lim, Jolander
Khoo, Audrey Y. T.
Flotow, Horst
Hill, Jeffrey
Dick, Thomas
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1128/mBio.00253-15Metadata
Show full item recordCitation
Moreira, W., G. J. Y. Ngan, J. L. Low, A. Poulsen, B. C. S. Chia, M. J. Y. Ang, A. Yap, et al. 2015. “Target Mechanism-Based Whole-Cell Screening Identifies Bortezomib as an Inhibitor of Caseinolytic Protease in Mycobacteria.” mBio 6 (3): e00253-15. doi:10.1128/mBio.00253-15. http://dx.doi.org/10.1128/mBio.00253-15.Abstract
ABSTRACT A novel type of antibacterial screening method, a target mechanism-based whole-cell screening method, was developed to combine the advantages of target mechanism- and whole-cell-based approaches. A mycobacterial reporter strain with a synthetic phenotype for caseinolytic protease (ClpP1P2) activity was engineered, allowing the detection of inhibitors of this enzyme inside intact bacilli. A high-throughput screening method identified bortezomib, a human 26S proteasome drug, as a potent inhibitor of ClpP1P2 activity and bacterial growth. A battery of secondary assays was employed to demonstrate that bortezomib indeed exerts its antimicrobial activity via inhibition of ClpP1P2: Down- or upmodulation of the intracellular protease level resulted in hyper- or hyposensitivity of the bacteria, the drug showed specific potentiation of translation error-inducing aminoglycosides, ClpP1P2-specific substrate WhiB1 accumulated upon exposure, and growth inhibition potencies of bortezomib derivatives correlated with ClpP1P2 inhibition potencies. Furthermore, molecular modeling showed that the drug can bind to the catalytic sites of ClpP1P2. This work demonstrates the feasibility of target mechanism-based whole-cell screening, provides chemical validation of ClpP1P2 as a target, and identifies a drug in clinical use as a new lead compound for tuberculosis therapy.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436076/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:16120871
Collections
- HMS Scholarly Articles [17922]
- SPH Scholarly Articles [6362]
Contact administrator regarding this item (to report mistakes or request changes)